Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Eighty-two patients were entered. There were 14 deaths (nine early), mostly from documented or presumed bacterial or fungal sepsis. Overall, 30 patients achieved complete remission (37%). These were mostly of brief duration--only one patient was still alive at 600+ days after BMT. CONCLUSIONS:
|
Authors | M L Bernstein, T C Abshire, B H Pollock, S Devine, S Toledano, C P Steuber, W P Bowman, G R Buchanan |
Journal | Journal of pediatric hematology/oncology
(J Pediatr Hematol Oncol)
1997 Jan-Feb
Vol. 19
Issue 1
Pg. 68-72
ISSN: 1077-4114 [Print] United States |
PMID | 9065722
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Child
- Child, Preschool
- Cytarabine
(administration & dosage)
- Humans
- Idarubicin
(administration & dosage)
- Infusions, Intravenous
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy, pathology)
- Recurrence
- Treatment Outcome
|